Related Experiment Videos
Nonmyeloablative therapy and allogeneic hematopoietic stem cell transplantation
Imad A Tabbara1, Richard M Ingram
1University of Virginia Health System, Charlottesville, VA 22908-0716, USA. iat2b@virginia.edu
Experimental Hematology
|July 5, 2003
Summary
Conventional myeloablative therapy and allogeneic hematopoietic stem cell transplantation (SCT) have toxicities limiting their use. Newer approaches focus on donor T-lymphocyte infusions to improve outcomes in cancer treatment.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Conventional myeloablative therapy and allogeneic hematopoietic stem cell transplantation (SCT) are potentially curative but limited by significant toxicities.
- Treatment-related morbidity and mortality range from 10% to 50% in allogeneic SCT, influenced by patient age, HLA compatibility, and disease status.
Purpose of the Study:
- To explore newer treatment modalities for allogeneic SCT that mitigate toxicity.
- To investigate the role of immune-mediated effects from donor T-lymphocytes in preventing leukemic relapse.
Main Methods:
- Development of newer treatment modalities focusing on host tolerance induction.
- Administration of scheduled donor T-lymphocyte infusions.
Main Results:
- Conventional myeloablative regimens may not fully eradicate malignancy.
- An immune-mediated effect from donor T-lymphocytes appears crucial for therapeutic benefit and lower leukemic relapse rates compared to autologous or syngeneic SCT.
Conclusions:
- Newer approaches involving donor T-lymphocyte infusions show encouraging preliminary results.
- Further prospective controlled trials are needed to confirm efficacy, durability, and long-term complications like chronic graft-vs-host disease.